NEWS

Sensus Healthcare, Inc. Prices Initial Public Offering

Press Release



June 02, 2016

Boca Raton, FL

Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced the pricing of its initial public offering of 2,000,000 units at a public offering price of $5.50 per unit, before underwriting discounts and commission. Each unit consists of one share of common stock, $0.01 par value per share, and a three-year warrant to purchase one share of common stock at an initial exercise price of $6.75 per share. All of the units are being offered by Sensus. In addition, Sensus has granted the underwriters a 45-day option to purchase up to 300,000 additional units at the initial public offering price, less underwriting discounts and commissions. The units will commence trading on The NASDAQ Capital Market on Friday, June 3, 2016, under the ticker symbol “SRTSU.”  The offering is expected to close on or about June 8, 2016, subject to satisfaction of customary closing conditions.

On or prior to July 25, 2016, the units will separate into each of its components and each such component security will begin trading separately on The NASDAQ Capital Market. The common stock is expected to trade under the symbol “SRTS,” while the warrants are expected to trade under the ticker symbol “SRTSW.” Sensus will issue a press release announcing the date such separate trading will begin.

Northland Securities, Inc., and Neidiger, Tucker, Bruner, Inc. are acting as joint book-running managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 2, 2016. When available, copies of the final prospectus related to the offering may be obtained from Northland Securities by mail at 750 Third Ave, Suite 2401, New York, NY 10017, by calling: (800) 851-2920, or by email:ahammer@northlandcapitalmarkets.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Sensus

Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.

Investor Relations:
Kim Golodetz
LHA Investor Relations
Phone: 212-838-3777
Email: kgolodetz@lhai.com

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

  1. 95%+ cure rates that rival surgery
  2. No anesthesia, cutting, bleeding, stitching or pain
  3. No downtime or lifestyle restrictions
  4. Super cosmesis, no unsightly scarring
  5. No need for post-treatment reconstructive surgeries